Similar articles

• Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.

  Aoyama T, Murakawa M, Katayama Y, Shiozawa M, Ueno M, Morimoto M, Yoshikawa T, Rino Y, Masuda M, Morinaga S. Aoyama T, et al. Hepatogastroenterology. 2015 Mar-Apr;62(138):472-7. Hepatogastroenterology. 2015. PMID: 25916085
• [Chemotherapy and radiotherapy for inoperable pancreatic cancer. A survey of a Cochrane review].

  Bjerregaard JK, Pfeiffer P. Bjerregaard JK, et al. Ugeskr Laeger. 2007 Nov 12;169(46):3949-52. Ugeskr Laeger. 2007. PMID: 18078646 Review. Danish. No abstract available.
• [Chemoradiation therapy and immunotherapy for pancreatic cancer].

  Egawa S, Motoi F, Fukuyama S, Sunamura M, Unno M. Egawa S, et al. Nihon Rinsho. 2006 Jan;64 Suppl 1:258-63. Nihon Rinsho. 2006. PMID: 16457262 Review. Japanese. No abstract available.
• [Management of pancreatic cancer: current therapy and continued development].

  Tsukada K, Nagata T, Yoshino T. Tsukada K, et al. Nihon Rinsho. 2006 Jan;64 Suppl 1:175-9. Nihon Rinsho. 2006. PMID: 16457244 Review. Japanese. No abstract available.
• S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.

  Okabayashi T, Shima Y, Iwata J, Morita S, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Kosaki T, Kobayashi M, Hanazaki K. Okabayashi T, et al. World J Surg. 2014 Nov;38(11):2986-93. doi: 10.1007/s00268-014-2703-z. World J Surg. 2014. PMID: 25104544